Mortality benefit derived from SGLT2 inhibition could extend to HF with improved EF

Dapagliflozin plus guideline-directed medical therapy may reduce CV death in patients with HF with improved ejection fraction by lowering risk for sudden death, researchers reported.
Findings from a post hoc analysis of the DELIVER trial assessing mode of death among patients with HF with improved EF treated with dapagliflozin (Farxiga, AstraZeneca) compared with placebo were published in JAMA Cardiology.
“Patients with heart failure with improved ejection fraction, defined as prior left ventricular ejection fraction 40% or lower that has increased to greater than 40%, represent an

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart